Literature DB >> 16108011

Osteoporosis in Parkinson's disease.

Brian Wood1, Richard Walker.   

Abstract

There are few studies of osteoporosis in Parkinson's disease (PD). We assessed the prevalence of osteoporosis in a PD clinic cohort. All subjects with a confirmed diagnosis of PD attending a clinic were invited to participate. All consenting subjects had bone density measured by dual energy X-ray absorptiometry scanning. Further data, including demography, disease duration, and disease severity, were collected. One hundred five subjects participated; median age was 75 (54-92) years. Fifty-one (49%) patients were men. Of the men: median T score, -1.3 (range, -4.7 to 3.8); median Z score, 0.0 (-3.2 to 4.7); diagnostic categories: osteoporosis, 20%; osteopenia, 41%; normal, 39%. Of the women: median T score -2.7 (-4.7 to 1.4); median Z score, -0.25 (-2.6 to 4.2); diagnostic categories: osteoporosis, 63%; osteopenia, 28%; and normal, 9%. Whole sample: osteoporosis, 42%; osteopenia, 34%; and normal, 24%. There were associations between age, depression, disease duration, and osteoporosis but not with disease severity. Female gender was an independent predictor of osteoporosis. The prevalence of osteoporosis/osteopenia is considerable in PD patients but does not exceed that of other people of similar age. Osteoporosis/osteopenia was present in almost all women of this age group with PD.

Entities:  

Mesh:

Year:  2005        PMID: 16108011     DOI: 10.1002/mds.20643

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

1.  Prevalence and risk factors of osteoporosis in patients with Parkinson's disease.

Authors:  A Bezza; Z Ouzzif; H Naji; L Achemlal; A Mounach; M Nouijai; A Bourazza; R Mossadeq; A El Maghraoui
Journal:  Rheumatol Int       Date:  2008-07-01       Impact factor: 2.631

Review 2.  Musculoskeletal problems in Parkinson's disease.

Authors:  Young Eun Kim; Beom S Jeon
Journal:  J Neural Transm (Vienna)       Date:  2013-02-19       Impact factor: 3.575

3.  Whole body vibration therapy in fracture prevention among adults with chronic disease.

Authors:  Marco Yc Pang
Journal:  World J Orthop       Date:  2010-11-18

4.  Bone mineral density and vitamin D status in Parkinson's disease patients.

Authors:  F van den Bos; A D Speelman; M van Nimwegen; Y T van der Schouw; F J G Backx; B R Bloem; M Munneke; H J J Verhaar
Journal:  J Neurol       Date:  2012-10-09       Impact factor: 4.849

5.  Osteoporosis and Parkinson's disease.

Authors:  Laura Maria Raglione; Sandro Sorbi; Benedetta Nacmias
Journal:  Clin Cases Miner Bone Metab       Date:  2011-09

6.  Fracture risk in Parkinson's disease according to its severity and duration.

Authors:  Hye Yeon Koo; Eun Bin Cho; Sung Hye Kong; Kyungdo Han; Kyu Na Lee; Jung Eun Yoo; Ju-Hong Min; Sohyun Chun; Dong Wook Shin
Journal:  Osteoporos Int       Date:  2022-10-07       Impact factor: 5.071

Review 7.  Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

Authors:  S Binks; R Dobson
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

8.  Components of air pollution and cognitive function in middle-aged and older adults in Los Angeles.

Authors:  Nicole M Gatto; Victor W Henderson; Howard N Hodis; Jan A St John; Fred Lurmann; Jiu-Chiuan Chen; Wendy J Mack
Journal:  Neurotoxicology       Date:  2013-10-19       Impact factor: 4.294

9.  Lower Bone Mineral Density in Patients with Parkinson's Disease: A Cross-Sectional Study from Chinese Mainland.

Authors:  Huimin Gao; Xiaobo Wei; Jinchi Liao; Rui Wang; Jiehua Xu; Xu Liu; Xiaoping Pan; Ze Li; Zhong Li; Ying Xia; Qing Wang
Journal:  Front Aging Neurosci       Date:  2015-10-27       Impact factor: 5.750

10.  A quality improvement initiative on the management of osteoporosis in older people with Parkinsonism.

Authors:  Inderpal Singh; Rachel Fletcher; Linda Scanlon; Mandy Tyler; Shridhar Aithal
Journal:  BMJ Qual Improv Rep       Date:  2016-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.